11th Translational Research Conference
Myeloproliferative Neoplasms
April 24-26, 2026 – Estoril, Portugal
Chairpersons: Jean-Jacques Kiladjian, Ross L. Levine, Ann Mullally, Jyoti Nangalia

Friday, April 24th, 2026

08:30-08:40 Welcome: Jean-Jacques Kiladjian, Ross L. Levine, Ann Mullally, Jyoti Nangalia

SESSION I – Somatic evolution and MPN
Chair: Jyoti Nangalia (Cambridge)

08:40-08:45	Introduction	Jyoti Nangalia (Cambridge)
08:45-09:15	**Keynote Lecture:** Novel insights in megakaryopoiesis	Bethan Psaila (Oxford)
09:15-09:20	*Discussion*	
09:20-09:35	Is curing MPN a dream or a potential reality?	Claire Harrison (London)
09:35-09:40	*Discussion*	
09:40-09:55	Clonal selection in blood and skin during MPN therapy	Lina Benajiba (Paris)
09:55-10:00	*Discussion*	
10:00-10:07	*Selected brief oral communication* *Deciphering fibrotic niches in MPN using NicheSphere: a multicellular interaction blueprint in bone marrow fibrosis*	*Hélène Gleitz (Rotterdam)*
10:07-10:10	*Discussion*	
10:10-10:40	*Panel discussion*	

10:40-11:10 Coffee Break

SESSION II – New approaches for targeting MPN
Chair: Stefan Constantinescu (Brussels)

11:10-11:15	Introduction	Stefan Constantinescu (Brussels)
11:15-11:30	Targeting iron metabolism in PV	Andrew Kuykendall (Tampa)
11:30-11:35	*Discussion*	
11:35-11:50	Type II JAK inhibition in MPNs	Sara Meyer (Bern)
11:50-11:55	*Discussion*	

11:55-12:10	Strategies for CALR targeting	Alexandros Rampotas (London)
12:10-12:15	*Discussion*	
12:15-12:22	*Selected brief oral communication* *Direct inhibition of RAS enhances JAK2 inhibitor therapy in preclinical models of MPN*	*Gary Reuther (Tampa)*
12:22-12:25	*Discussion*	
12:25-12:55	*Panel discussion*	
12:55-14:50	***Lunch***	

13:40-14:40 **SATELLITE SYMPOSIUM**
Going beyond spleen and symptoms in myelofibrosis
Chair: Claire Harrison (London)
Speakers: Valentín García Gutiérrez (Madrid), Daniela Cilloni (Turin), Claire Harrison (London)

This symposium is organised and sponsored by Menarini Stemline

SESSION III – New causes and classification
Chair: Claire Harrison (London)

14:50-14:55	Introduction	Claire Harrison (London)
14:55-15:10	Inflamed: genotype and cell-type specific heterogeneity in MPN	Ann Mullally (Stanford)
15:10-15:15	*Discussion*	
15:15-15:30	EPO regulation and erythrocytosis	Salam Idriss (Nantes)
15:30-15:35	*Discussion*	
15:35-15:50	Triple negative thrombocytosis – new proposed classification	Anna Godfrey (Cambridge)
15:50-15:55	*Discussion*	
15:55-16:02	*Selected brief oral communication* *Redefining the Myeloproliferative Neoplasm Continuum: A Machine Learning Approach to Disease Evolution and Prognostic Stratification*	*Yu-Hung Wang (Taipei)*
16:02-16:05	*Discussion*	
16:05-16:35	*Panel discussion*	
16:35-17:05	***Coffee break***	

SESSION IV – Recent developments in blast phase MPN
Chair: Steve Lane (Brisbane)

17:05-17:10	Introduction	Steve Lane (Brisbane)
17:10-17:25	Molecular routes to blast crisis in MPN	Charlotte Brierley (Oxford)
17:25-17:30	*Discussion*	

17:30-17:45	Transcriptional dysregulation in blast crisis MPN	Stephen Oh (St. Louis)
17:45-17:50	*Discussion*	
17:50-18:05	Emerging therapeutic approaches in blast phase MPN	Florian Heidel (Hannover)
18:05-18:10	*Discussion*	
18:10-18:17	*Selected brief oral communication* *Epigenetic age acceleration independently predicts hematological transformation in myeloproliferative neoplasms*	*Olivier Mansier (Bordeaux)*
18:17-18:20	*Discussion*	
18:20-18:50	*Panel discussion*	
18:55-21:00	**Mentored Poster Walks and Welcome Get-Together #1** Biology Poster Walk Leaders: Steve Lane (Brisbane), Bethan Psaila (Oxford) Clinical Poster Walk Leaders: Florian Heidel (Hannover), Sara Meyer (Bern)	

Saturday, April 25th, 2026

07:50-08:50	**3 Simultaneous Meet the Expert sessions (non-clinical)**	
	1, Mechanisms of skin cancer development during MPN	Lina Benajiba (Paris)
	2, Familial MPNs - causes and molecular mechanisms	Radek Skoda (Houston)
	3, Targeting CALR mutations	Shannon Elf (Salt Lake City)

09:00-10:00 **SATELLITE SYMPOSIUM**
Advancing Myelofibrosis Care: From Unmet Needs to Emerging Therapies and the Path Forward
Chair: Martin Griesshammer (Minden)
Speakers: Martin Griesshammer (Minden), Claire Harrison (London), Lina Benajiba (Paris)

This symposium is organised and sponsored by Novartis

10:00-10:30 ***Coffee break***

SESSION V – Novel functional insights downstream of JAK/CALR/MPL
Chair: Ann Mullally (Stanford)

10:30-10:35	Introduction	Ann Mullally (Stanford)
10:35-10:50	New functions of JAK2 - not so jumping Jak....	Stephen Loughran (Cambridge)
10:50-10:55	*Discussion*	
10:55-11:10	Type 1 versus Type 2 mutations in CALR	Shannon Elf (Salt Lake City)
11:10-11:15	*Discussion*	
11:15-11:30	Molecular targeting of MPN driver lesions, lessons from the lab and the clinic	Ross L. Levine (New York)
11:30-11:35	*Discussion*	

11:35-11:42	*Selected brief oral communication* *The cooperation between CALRdel52 and TP53 mutations increases the number of immature hematopoietic progenitors and enhances the CALRdel52-induced megakaryocytic bias*	*Barbara Monte Mor (Rio de Janeiro)*
11:42-11:45	*Discussion*	
11:45-12:15	*Panel discussion*	
12:15-14:10	***Lunch***	

13:00-14:00 **SATELLITE SYMPOSIUM**

Patient-centered approaches in myelofibrosis: Tailoring treatment for anemia and thrombocytopenia

Chair: Jean-Jacques Kiladjian (Paris)

Speakers: Jean-Jacques Kiladjian (Paris), Steffen Koschmieder (Aachen), Claire Harrison (London)

This independent symposium is organized by SES on behalf of the MPN Hub and funded by GSK. GSK are allowed no influence on the content of this symposium

SESSION VI – MPN management
Chair: Jean-Jacques Kiladjian (Paris)

14:10-14:15	Introduction	Jean-Jacques Kiladjian (Paris)
14:15-14:30	Interferon resistance - what is it and how to identify it?	Marta Sobas (Bydgoszcz)
14:30-14:35	*Discussion*	
14:35-14:50	Molecular dynamics and outcomes – moving the dial to new trial endpoints?	Jennifer O'Sullivan (London)
14:50-14:55	*Discussion*	
14:55-15:10	Thrombosis and bleeding in MPNs	Chloe James (Bordeaux)
15:10-15:15	*Discussion*	
15:15-15:22	*Selected brief oral communication* *Multiomic Single-Cell Analysis Reveals Determinants of JAK Inhibitor Efficacy in Myelofibrosis*	*Chiara Carretta (Modena)*
15:22-15:25	*Discussion*	
15:25-15:55	*Panel discussion*	
15:55-16:25	***Coffee break***	

SESSION VII – Disease mechanisms in MPN
Chair: Stephen Oh (St. Louis)

16:25-16:30	Introduction	Stephen Oh (St. Louis)
16:30-16:45	Mechanism of fibrosis in MPNs	Rebekka Schneider-Kramann (Aachen)
16:45-16:50	*Discussion*	

16:50-17:05	Recent therapeutic advances in Myeloproliferative Neoplasms (MPNs)	Ruben Mesa (Charlotte)
17:05-17:10	*Discussion*	
17:10-17:25	MPN development - putting it into evolutionary context	Jyoti Nangalia (Cambridge)
17:25-17:30	*Discussion*	
17:30-17:37	*Selected brief oral communication* *Inhibition of JAK2V617F-Driven Neoplastic Endothelial Dysfunction by IFN-alpha as a Novel Antifibrotic Mechanism*	*Steffen Koschmieder (Aachen)*
17:37-17:40	*Discussion*	
17:40-18:10	*Panel discussion*	
18:15-19:15	**Mentored Poster Walks #2** Biology Poster Walk Leaders: Lina Benajiba (Paris), Stephen Oh (St. Louis) Clinical Poster Walk Leaders: Andrew Kuykendall (Tampa), Jennifer O'Sullivan (London)	

Sunday, April 26th, 2026

07:30-08:30	**3 Simultaneous Breakfast Meet the Expert Sessions (Clinical)**	
	1, How to manage iron deficiency in PV	Marta Sobas (Bydgoszcz)
	2, VAF reduction in MPN - is it clinically important?	Jennifer O'Sullivan (London)
	3, Managing thrombosis and bleeding	Chloe James (Bordeaux)

SESSION VIII – Aberrant cell populations in MPN
Chair: Rebekka Schneider-Kramann (Aachen)

08:35-08:40	Introduction	Rebekka Schneider-Kramann (Aachen)
08:40-08:55	Clonal evolution early detection of blast phase transformation	Steve Lane (Brisbane)
08:55-09:00	*Discussion*	
09:00-09:15	Mutant HSC dysregulation in MPN	Radek Skoda (Houston)
09:15-09:20	*Discussion*	
09:20-09:35	Interferon in MPN: where do we stand in 2026?	Jean-Jacques Kiladjian (Paris)
09:35-09:40	*Discussion*	
09:40-09:47	*Selected brief oral communication* *Autosomal-dominant hereditary thrombocythemia caused by an 11 bp duplication in Calreticulin*	*Julia Teders (Nijmegen)*
09:47-09:50	*Discussion*	
09:50-10:20	*Panel discussion*	
10:20-10:50	***Coffee break***	

SESSION IX – New frontiers in MPN, where is the field going?
Chair: Ruben Mesa (Charlotte)

10:50-10:55	Introduction	Ruben Mesa (Charlotte)
10:55-11:25	**Keynote Lecture :** Structural and conformational targets in phenotypic and clonal driver mutant proteins in MPNs and sAML	Stefan Constantinescu (Brussels)
11:25-11:30	*Discussion*	
11:30-11:45	Mathematically modelling the emergence of MPN	Stephane Giraudier (Paris)
11:45-11:50	*Discussion*	
11:50-12:05	Vaccination strategies - Can we prevent MPN?	Morten Orebo Holmström (Copenhagen)
12:05-12:10	*Discussion*	
12:10-12:17	*Selected brief oral communication* *HMGA1 Chromatin Regulators Disrupt 3D Genome Architecture and Chromatin Looping to Repress Antigen Presenting Genes and Drive Immune Evasion Networks during MPN Progression*	*Linda Resar (Baltimore)*
12:17-12:20	*Discussion*	
12:20-12:50	*Panel discussion*	
12:50-13:00	***Closing Remarks***	

MEETING CLOSURE